The primary endpoint was the proportion of subjects without a disease progression to severity according to COVID-19 guidelines by the National Institutes of Health (NIH) since randomization to 14 days.

On day 42, Spike IgG geometric mean ELISA titers were 0.8, 211, and 590 Spike binding antibody units (BAU/mL) for placebo, low-dose and high-dose ECV19, respectively (p  0.001 between groups).

Trial Registration ClinicalTrials.gov NCT04508972; https://clinicaltrials.gov/ct2/show/NCT04508972 International Registered Report Identifier (IRRID) DERR1-10.2196/41209

However, its utility among spontaneously breathing patients is still debated.MethodsIn an open-label randomized controlled trial, we enrolled patients hospitalized with mild COVID-19 pneumonia, whose PaO2/FiO2 ratio was 200 mmHg and who did not require mechanical ventilation (MV) or non-invasive ventilation (NIV) at hospital admission.

ObjectiveTo study the COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis (MG).

Aim: We previously published results of the BATTLE trial, showing that patients recently infected with SARS-CoV-2 can benefit from receiving Bacillus Calmette-Guérin (BCG) with minimal adverse effects.

Treatment effectiveness at various time lags since the first positive RT-PCR swab test was measured by rate of events in the experimental arm (EER) and in the control arm (CER), absolute risk increase (ARI) = (EER − CER), and number needed to treat (NNT) = (1/ARI).

ABSTRACTBACKGROUNDThis study has assessed a new Anti-COVID-19 Monoclonal Antibody Nasal Spray (SA58) for post-exposure prophylaxis (PEP) against symptomatic coronavirus disease 2019 (COVID-19).METHODSWe conducted an efficacy study in adults aged 18 years and older within three days of exposure to a SARS-CoV-2 infected individual.

The eradication rates in intention to treat (ITT) and per protocol (PP) analyses were: group I, 55.56% and 64.66%; and Group II, 64.44% and 74.36% respectively (p = 0.11).

Saliva was collected every day and viral load was measured by quantitative reverse transcription-polymerase chain reaction (qRT-PCR).